Y-Biologics, Inc. (KOSDAQ:338840)

Market Cap	276.39B +142.2%
Revenue (ttm)	2.91B -49.5%
Net Income	-42.02B
EPS	-2,821.86
Shares Out	15.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	113,330
Average Volume	193,963
Open	18,890
Previous Close	19,550
Day's Range	18,320 - 19,700
52-Week Range	7,550 - 38,000
Beta	n/a
RSI	29.37
Earnings Date	n/a

About Y-Biologics

Y-Biologics, Inc., an antibody therapeutics development company, engages in the research and development of immuno-oncology drugs and antibody drugs. The company develops YBL-006, a PD-1 immune-oncology agent that is phase 1 clinical stage for the treatment of solid tumor. It also develops immunoregulatory monoclonal antibodies, such as YBL-011 and AR062 for the treatment of solid cancers; AR166, AR169, and AR170 for solid cancers; and AR153, a pH-dependent antibody for the treatment of solid cancer. Y-Biologics, Inc. was incorporated in 2007 a...

• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 338840

Financial Performance

In 2025, Y-Biologics's revenue was 2.91 billion, a decrease of -49.45% compared to the previous year's 5.76 billion. Losses were -42.02 billion, 552.4% more than in 2024.